NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Tuesday that its first quarter revenues were up 6 percent year over year driven by increased sales for its Oncotype DX tests.

The Redwood City, Calif.-based molecular diagnostics firm brought in total revenues of $67 million for the three months ended March 31, up from $63.1 million in the first quarter of 2013 but below the consensus Wall Street estimate of $68.5 million. All of its revenue in the most recent quarter came from product sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.